Potential applications for inPROBE
Advancing cancer diagnostics
The inPROBE technology offers a potential advancement in cancer diagnostics by enabling real-time detection of HER2 expression across various cancer types. The proof of concept achieved with HER2 biomarker detection suggests that this technology could also be considered for use with other biomarkers.
In breast cancer, inPROBE offers a potential advancement by enabling real-time detection of HER2 receptor concentrations. This approach provides insights that may complement standard diagnostic methods, such as IHC and ISH, ultimately improving HER2 status determination and informing patient management.
In gastric cancer, inPROBE has shown promise in assessing HER2 status in peritoneal lavage samples during diagnostic laparoscopy. By enabling real-time detection, this technology may enhance the precision of diagnostics and assist in identifying patients who could benefit from targeted therapies.
HER2 biomarker overexpression in cancer
HER2-expressing cancers are a group of aggressive tumors often associated with faster progression and a poorer prognosis. These include breast, gastric, lung and a range of other cancers.
While HER2 positivity can accelerate tumor growth, targeted therapies have significantly improved patient outcomes. Accurate assessment of HER2 status is essential for selecting optimal treatments and advancing precision medicine research.
